|
Post by lcd on Feb 9, 2015 21:29:06 GMT
dayan, Looks like you were not the only one feeling bullish after the presentation. The share price went up almost $.20 in the last half hour of trading.
I bought more on Friday and am averaged in at $3.10. I will probably double my holdings over the next month because I do feel like it will hit a new 52 week high ($4.81 or about $420 million market cap) heading into results.
|
|
|
Post by forthefuture on Feb 9, 2015 21:38:55 GMT
The presentation today was very strong. Not pumpy, but let known some key dates including ALS Ph2 data within a month, Stroke ph1 enrollment completion (and potentially data) Q1, MDD full data publication Q1/Q2, MDD ph2 start Q2 start of second NSI-189 indication later this year (in cognitive deficit caused by schizophrenia), ALS ph2b trial start Q2/Q3, cSCI data Q4. Lots of shots on goal for transformative efficacy results.
|
|
|
Post by RLC on Feb 9, 2015 21:50:01 GMT
dayan, Looks like you were not the only one feeling bullish after the presentation. The share price went up almost $.20 in the last half hour of trading. I bought more on Friday and am averaged in at $3.10. I will probably double my holdings over the next month because I do feel like it will hit a new 52 week high ($4.81 or about $420 million market cap) heading into results. I almost grabbed some shares here based on the discussions that have been taking place, however I wouldn't allow myself to do so because I really haven't dug into this company yet. I'm going to take a strong look at this tonight and might open a small position sometime this week. Congrats to all holding!
|
|
|
Post by Yelk on Feb 9, 2015 22:03:14 GMT
After market activity today too. I can't wait to get home and go through some presentations.
|
|
|
Post by Yelk on Feb 10, 2015 2:35:16 GMT
I got a chance to listen to the full webcast. Looks good. I like to analyze these CEO's when they present to try and get a hint of what they think of data. Maybe I'm being overly cautious but there was one line in there I didn't like. He basically said: "I want to really express what we are trying to achieve in this study" I've seen this phrase a lot to soften the blow of bad data.
Now I really read ALOT into that. I am still fully leaning towards positive data due to DD on science, BCLI success, others opinions, DR. EVA's presentation, recent comments on presentations and most importantly patients blogs from this trial. ^ That is alot more convincing than one line - also I don't know this CEO very well. GLTA I think we can expect to see Data as early as the end of February! I intend to hold a meaningful position right through the data.
|
|
|
Post by jckrdu on Feb 10, 2015 3:09:56 GMT
Just got off from the presentation call. My gut feel was correct. TLD release is scheduled late feb or early march. I transferred some of athx funds into CUR. I am highly bullish about this stock leading to TLD results. Nice move Day... not a bad plan at all.
I don't own any CUR, but with today's news of Phase 2 data coming earlier than most had thought... combined with a pretty bullish chart (consolidating flag pattern at $3ish that looks ready to break out), I can see CUR hitting $4+ pretty easily prior to results.
That said, I'm going to stay concentrated in ATHX, as I'm still flipping coins to decide if ATHX will announce a partnership on stroke before results are announced.
Good luck to all CUR holders... near term looks pretty good IMO.
|
|
|
Post by dayanand33 on Feb 10, 2015 12:13:11 GMT
Just got off from the presentation call. My gut feel was correct. TLD release is scheduled late feb or early march. I transferred some of athx funds into CUR. I am highly bullish about this stock leading to TLD results. Nice move Day... not a bad plan at all.
I don't own any CUR, but with today's news of Phase 2 data coming earlier than most had thought... combined with a pretty bullish chart (consolidating flag pattern at $3ish that looks ready to break out), I can see CUR hitting $4+ pretty easily prior to results.
That said, I'm going to stay concentrated in ATHX, as I'm still flipping coins to decide if ATHX will announce a partnership on stroke before results are announced.
Good luck to all CUR holders... near term looks pretty good IMO.
I am expecting at least a 52 week high ($5). The pre-ponement of the results is going to surprise the market on the upside. The results are expected to be better than phase I mainly because of increase in dosage (more the better). Hope we see a repeat of the BCLI euphoria
|
|
|
Post by Yelk on Feb 10, 2015 14:26:07 GMT
Still holding pre-volume up same as post volume. I wouldn't expect too much this week. I could be wrong but I have a feeling it will be sharper towards week 16-20th of Feb. Might see some consolidation in this 3.30-3.50 range before next leg up.
|
|
|
Post by mycargoesfast on Feb 10, 2015 15:03:04 GMT
investor.neuralstem.com/index.php?s=126&item=168I thought it was interesting how many slides they dedicated to NSI-189 for MDD and Schizophrenia? (totally unexpected to me). Slide 14: This is a very sobering slide, I've seen ALS in action, most likely all 3 of these people would be dead or near dead by now if the disease ran its normal course. Why I like CUR as an investment: 1) The constantly update the public on the progression of their trial by putting a new presentation on their website every month. 2) They are driven and work fast and meet 90% of their timelines. 3) They are excited about what they do. I really hope they are able to sustain new highs this time, the last ride down was brutal and it wasn't because they did something wrong. There just wasn't any news to keep it proped up. I keep learning time and time again in biotech that it is a headline driven market, without headlines you can expect a slow steady erosion of the stock prices.
|
|
|
Post by Yelk on Feb 10, 2015 15:10:58 GMT
Ack wasn't expecting a spike like that rode the top of it when added at $3.45 what a noob move . Oh well heres for hoping high in weeks ahead.
|
|
|
Post by Yelk on Feb 10, 2015 15:12:08 GMT
investor.neuralstem.com/index.php?s=126&item=168I thought it was interesting how many slides they dedicated to NSI-189 for MDD and Schizophrenia? (totally unexpected to me). Slide 14: This is a very sobering slide, I've seen ALS in action, most likely all 3 of these people would be dead or near dead by now if the disease ran its normal course. Why I like CUR as an investment: 1) The constantly update the public on the progression of their trial by putting a new presentation on their website every month. 2) They are driven and work fast and meet 90% of their timelines. 3) They are excited about what they do. I really hope they are able to sustain new highs this time, the last ride down was brutal and it wasn't because they did something wrong. There just wasn't any news to keep it proped up. I keep learning time and time again in biotech that it is a headline driven market, without headlines you can expect a slow steady erosion of the stock prices. My Dads best friend died of ALS I called him Uncle growing up. Very familiar as well. Nice to have more than one reason to be in the stock.
|
|
|
Post by jckrdu on Feb 10, 2015 15:15:51 GMT
Opened a position at $3.30 at the open. See my post on ATHX board. Sold 10% of my ATHX holdings as a hedge and bought CUR in case ATHX CEO guides later than expected release of stroke data.
|
|
|
Post by Yelk on Feb 10, 2015 15:21:32 GMT
Opened a position at $3.30 at the open. See my post on ATHX board. Sold 10% of my ATHX holdings as a hedge and bought CUR in case ATHX CEO guides later than expected release of stroke data. Welcome aboard!
|
|
|
Post by jckrdu on Feb 10, 2015 15:23:01 GMT
Opened a position at $3.30 at the open. See my post on ATHX board. Sold 10% of my ATHX holdings as a hedge and bought CUR in case ATHX CEO guides later than expected release of stroke data. Welcome aboard! Thanks Yelk! I'm just here for a short-term trade. I plan to sell after results are announced and move it back into ATHX before stroke results.
|
|
|
Post by actcfan on Feb 10, 2015 15:54:07 GMT
Thanks Yelk! I'm just here for a short-term trade. I plan to sell after results are announced and move it back into ATHX before stroke results. I recently got in as well. I am of course hoping for great results but as a stockholder I'm not sure if I should sell before or after the results. Often seems before is the more optimal time.. thoughts?
|
|
|
Post by RLC on Feb 10, 2015 16:10:25 GMT
Thanks Yelk! I'm just here for a short-term trade. I plan to sell after results are announced and move it back into ATHX before stroke results. I recently got in as well. I am of course hoping for great results but as a stockholder I'm not sure if I should sell before or after the results. Often seems before is the more optimal time.. thoughts? I'm thinking the exact same thing actcfan. If you look back at the 10 or so companies this board has tracked over the last year that have had a significant data release, I'm pretty sure you would have been better selling prior to data release (Ex: ACTC/OCAT, BCLI, ONCS, NRIFF, ATHX w/ UC data, etc.). All had exceptional moves up prior to the data release, followed by a sharp move down when the data was actually released. I don't think I'm going to allow myself to hold 100% through a data release again in my life, unless 1.) I am near certain the data will be a (positive) surprise (although I did feel this way about ACTC/OCAT and got burned) OR 2.) my position is small enough that I can live with a ~50% loss. With CUR, I'm likely going to be selling 1/2 before and 1/2 after, but obviously things can change from now until then. Best of luck to all!
|
|
|
Post by lcd on Feb 10, 2015 17:10:22 GMT
I think P2 results are still too earlier to support a huge jump in market cap so if this run up approaches the 52-week high, I expect to sell out completely before results are announced. If the run up stays under $4 then I will probably stick around for the results.
Of course, when the time comes to actually sell I always get greedy and keep some shares hoping the pps will do another jump. This worked great for me with YHOO last year, but not so much with BCLI last month.
|
|
|
Post by JHam on Feb 10, 2015 17:33:36 GMT
Good luck guys! I am staying on the sidelines with this one, simply because I am to "in" with other stock right now. I haven't listened to the presentation, but the thinking here seems sound. As RLC just stated above, if history stays true to form, there will be a nice run up here soon.
So many nice opportunities right now in biotech.
|
|
|
Post by Yelk on Feb 11, 2015 0:42:58 GMT
Anyone else notice there is Phase Ibdata; Dr. Maurizio Fava 1Q/2Q15 on slide 17 same release time as ALS. I don't know if this or the later quarter data is big at all or not I need to do more DD on it tonight or tomorrow. Is it possible we get news before ALS news?
|
|
|
Post by jckrdu on Feb 11, 2015 0:57:23 GMT
Anyone else notice there is Phase Ibdata; Dr. Maurizio Fava 1Q/2Q15 on slide 17 same release time as ALS. I don't know if this or the later quarter data is big at all or not I need to do more DD on it tonight or tomorrow. Is it possible we get news before ALS news? Possible, but I don't think so. There's conflicting information on the slides as another slide just says completion of the stroke trial in Japan in 1st Qtr. If they're just guiding for completing the trial in 1st Qtr, I don't think they'll be releasing any data... but I'm not sure, anything's possible I guess.
|
|